Vasopressin in Liver Disease - Should We Turn On or Off?

E-ISSN： 2212-3938|3|3|156-165

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.3, Iss.3, 2008-09, pp. : 156-165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?

By Malindretos Pavlos

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2255-2256

Informa Healthcare

Access to resources Recommend Favorite

The high mobility group A1 molecular switch: turning on cancer – can we turn it off?

By Huso Tait H Resar Linda MS

Expert Opinion on Therapeutic Targets, Vol. 18, Iss. 5, 2014-05 ,pp. : 541-553

Informa Healthcare

Access to resources Recommend Favorite

Anti-TNF and Crohn's Disease: When Should we Start?

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 143-147

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-TNF and Crohn's Disease: When Should We Stop?

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 148-151

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [ Hot Topic: Drugs Targets in Parkinson's Disease:Where Are We and Where should We Go? (Guest Editor: Mark R. Cookson)]

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 10, Iss. 6, 2011-09 ,pp. : 650-650

Bentham Science Publishers

Access to resources Recommend Favorite